(Reuters) – Investment firm All Blue Capital would be advised by Alan Barge, former oncology head at British drugmaker AstraZeneca Plc, in its bid to acquire drug developer Zymeworks Inc, according to a press statement seen by Reuters. All Blue late last month approached Vancouver, Canada-based Zymeworks, which is developing antibody therapies for cancer, with a $773 million acquisition offer. Barge recently joined All Blue as oncology drug development advisor and would assist the firm in “reversing the value-destructive measures” that Zymeworks implemented over the past twelve months, accordi…